#1 Clinical Trials Search in Europe

Autologous Tumor Lysate-Loaded Dendritic Cells

This article examines ongoing clinical trials investigating the use of autologous tumor lysate-loaded dendritic cell vaccines for treating different types of cancer. These innovative immunotherapy treatments aim to harness the power of a patient’s own immune system to fight cancer cells. The trials focus on various cancer types, including neuroendocrine tumors, soft tissue sarcomas, glioblastoma, and colorectal cancer, exploring the safety, efficacy, and potential benefits of this personalized approach to cancer treatment.

Table of Contents

What is Autologous Tumor Lysate-Loaded Dendritic Cells?

Autologous Tumor Lysate-Loaded Dendritic Cells, also known as DC-VACCINE_IRSTIRCCS, is a type of personalized cancer treatment that falls under the category of immunotherapy[1]. This innovative approach uses your own immune system to fight cancer. Let’s break down what this means:

  • Autologous: This means the treatment is made from your own cells.
  • Tumor Lysate: This refers to the contents of cancer cells that have been broken down.
  • Loaded: The tumor lysate is combined with specific immune cells.
  • Dendritic Cells: These are special immune cells that help your body recognize and fight off threats, including cancer cells.

How Does It Work?

The process of creating and using this treatment involves several steps:

  1. A sample of your tumor is collected during surgery.
  2. Your dendritic cells are collected through a process called leukapheresis, where blood is drawn and specific cells are separated out[2].
  3. In a laboratory, your dendritic cells are exposed to the broken-down tumor cells (lysate).
  4. This “teaches” your dendritic cells to recognize the specific markers on your cancer cells.
  5. The prepared dendritic cells are then given back to you as a vaccine.
  6. Once in your body, these cells help your immune system identify and attack cancer cells more effectively.

What Conditions Does It Treat?

Autologous Tumor Lysate-Loaded Dendritic Cells are being studied for several types of cancer, including:

  • Neuroendocrine Tumors (NET): These are rare tumors that can occur in various parts of the body[1].
  • Soft Tissue Sarcoma (STS): A type of cancer that begins in the soft tissues of the body[1].
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord[2].
  • Colorectal Cancer: Cancer that starts in the colon or rectum[3][4].

It’s important to note that this treatment is currently being studied in clinical trials and is not yet widely available outside of research settings.

How Is It Administered?

The vaccine is typically administered through intradermal injection, which means it’s injected just under the skin[1]. The treatment schedule can vary depending on the specific study, but it often involves multiple doses over several months.

Current Clinical Trials

Several clinical trials are currently underway to study the effectiveness of Autologous Tumor Lysate-Loaded Dendritic Cells in different types of cancer:

  • A study for patients with resected stage IV neuroendocrine tumors and soft tissue sarcoma[1].
  • A trial for patients with glioblastoma, combining the dendritic cell vaccine with other treatments[2].
  • Studies for patients with metastatic colorectal cancer, including one that combines the vaccine with other immunotherapy and chemotherapy drugs[3][4].

Potential Side Effects

As with any medical treatment, there can be side effects. The clinical trials are designed to monitor these closely. Some potential side effects may include:

  • Reactions at the injection site
  • Flu-like symptoms
  • Fatigue

It’s important to note that the full range of potential side effects is still being studied in the ongoing clinical trials[1][1][2][3][4].

Conclusion

Autologous Tumor Lysate-Loaded Dendritic Cells represent a promising approach in cancer treatment. By harnessing the power of your own immune system, this therapy aims to provide a targeted and personalized way to fight cancer. While still in the research phase, ongoing clinical trials are helping to determine its effectiveness and safety for various types of cancer.

Aspect Details
Treatment Autologous tumor lysate-loaded dendritic cell vaccine
Cancer Types Studied Neuroendocrine tumors, soft tissue sarcomas, glioblastoma, metastatic colorectal cancer
Administration Method Intradermal injection
Primary Objectives Safety assessment, immunological efficacy evaluation
Secondary Objectives Clinical outcomes (PFS, OS), predictive factors identification, immune response persistence
Key Measurements Adverse events, immune response markers, tumor antigen expression, clinical response rates
Patient Selection Varies by study; generally includes adults with confirmed diagnosis, specific disease stages, and adequate organ function
Treatment Duration Varies by study; typically several months with follow-up periods
Combination Therapies Some trials combine the vaccine with other treatments (e.g., chemotherapy, immunotherapy drugs)

FAQ

  • What is an autologous tumor lysate-loaded dendritic cell vaccine? An autologous tumor lysate-loaded dendritic cell vaccine is a personalized cancer treatment made from a patient's own immune cells (dendritic cells) and tumor tissue. The dendritic cells are loaded with proteins from the patient's tumor, then given back to the patient to stimulate their immune system to recognize and attack cancer cells.
  • What types of cancer are being studied with this vaccine? The clinical trials are investigating the use of autologous tumor lysate-loaded dendritic cell vaccines for various cancer types, including neuroendocrine tumors, soft tissue sarcomas, glioblastoma (a type of brain cancer), and metastatic colorectal cancer.
  • How is the vaccine administered to patients? The vaccine is typically administered through intradermal injection, which means it is injected just beneath the skin. This method helps to stimulate the immune response effectively.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the safety of the treatment, evaluating its effectiveness in stimulating an immune response against cancer cells, measuring clinical outcomes such as progression-free survival and overall survival, and identifying potential predictive factors for treatment response.
  • Are there any common side effects associated with this treatment? While specific side effects can vary, the trials are closely monitoring for any adverse events. Common side effects of immunotherapies can include injection site reactions, flu-like symptoms, and fatigue. The studies aim to determine the type, incidence, and severity of any side effects associated with the treatment.

Ongoing Clinical Trials on Autologous Tumor Lysate-Loaded Dendritic Cells

  • Study on Aldesleukin and Dendritic Cell Vaccine for Patients with Resected Stage IV Neuroendocrine Tumors and Soft Tissue Sarcoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Dendritic Cell Vaccine and Aldesleukin Treatment in Patients After Surgery for Stage IV Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study of Pembrolizumab, Dendritic Cell Vaccine, Trifluridine/Tipiracil, and Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of a Dendritic Cell Vaccine and Temozolomide for Patients with Glioblastoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Autologous: Derived from the same individual. In this context, it refers to using the patient's own cells or tissue to create the vaccine.
  • Dendritic cells: Specialized immune cells that help the body recognize and fight foreign substances, including cancer cells.
  • Tumor lysate: A mixture of proteins and other components obtained from breaking down tumor tissue, used to 'teach' the immune system to recognize cancer cells.
  • Immunotherapy: A type of cancer treatment that stimulates the body's own immune system to recognize and destroy cancer cells.
  • Clinical trial: A research study that tests how well new medical approaches work in people, often used to evaluate new treatments for diseases like cancer.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.
  • Intradermal injection: A method of delivering a substance just beneath the skin, often used for vaccines to stimulate an immune response.
  • Leukapheresis: A medical procedure to separate and collect white blood cells from the blood, used in this case to obtain the patient's immune cells for vaccine production.
  • DTH test: Delayed-Type Hypersensitivity test, used to assess the body's immune response to specific substances.
  • ELISPOT: Enzyme-Linked ImmunoSpot, a laboratory technique used to measure immune responses at the cellular level.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord.
  • Neuroendocrine tumor: A type of tumor that begins in specialized cells called neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells.
  • Soft tissue sarcoma: A type of cancer that begins in the soft tissues of the body, including muscle, fat, blood vessels, nerves, and connective tissues.

References

  1. http://clinicaltrials.eu/trial/study-on-aldesleukin-and-dendritic-cell-vaccine-for-patients-with-resected-stage-iv-neuroendocrine-tumors-and-soft-tissue-sarcoma/
  2. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-a-dendritic-cell-vaccine-and-temozolomide-for-patients-with-glioblastoma/
  3. http://clinicaltrials.eu/trial/study-of-pembrolizumab-dendritic-cell-vaccine-trifluridine-tipiracil-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer/
  4. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-autologous-tumor-lysate-loaded-dendritic-cells-and-aldesleukin-for-patients-with-stage-iv-colorectal-cancer/